EA201070019A1 - 4,5-DIHYDRO- (1H) -PYRAZOL DERIVATIVES AS MODULATORS OF CANANABINOID ST-RECEPTORS - Google Patents

4,5-DIHYDRO- (1H) -PYRAZOL DERIVATIVES AS MODULATORS OF CANANABINOID ST-RECEPTORS

Info

Publication number
EA201070019A1
EA201070019A1 EA201070019A EA201070019A EA201070019A1 EA 201070019 A1 EA201070019 A1 EA 201070019A1 EA 201070019 A EA201070019 A EA 201070019A EA 201070019 A EA201070019 A EA 201070019A EA 201070019 A1 EA201070019 A1 EA 201070019A1
Authority
EA
Eurasian Patent Office
Prior art keywords
receptors
modulators
dihydro
compounds
methods
Prior art date
Application number
EA201070019A
Other languages
Russian (ru)
Inventor
Махмут Йилдирим
Хендрик К. Валс
Бернард Дж. Ван Влит
Йозефус Х.М. Ланге
Original Assignee
Солвей Фармасьютикалс Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Солвей Фармасьютикалс Б.В. filed Critical Солвей Фармасьютикалс Б.В.
Publication of EA201070019A1 publication Critical patent/EA201070019A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Child & Adolescent Psychology (AREA)

Abstract

Данное изобретение относится к 4,5-дигидро-(1Н)-пиразольным (пиразолиновым) производным в качестве модуляторов каннабиноидных CB-рецепторов, к фармацевтическим композициям, содержащим такие соединения, к способам их синтеза, способам получения новых промежуточных продуктов, применимых для их синтеза, и способам получения композиций. Изобретение также относится к применению таких соединений и композиций, в частности к их применению при введении их пациентам для обеспечения терапевтического эффекта при расстройствах, в которые вовлечены CB-рецепторы, или которые можно лечить путем воздействия на указанные рецепторы. Соединения имеют формулу (I), в которой символы имеют значения, приведенные в описании изобретенияThis invention relates to 4,5-dihydro- (1H) -pyrazole (pyrazoline) derivatives as modulators of cannabinoid CB receptors, to pharmaceutical compositions containing such compounds, to methods for their synthesis, methods for producing new intermediate products applicable for their synthesis , and methods for producing compositions. The invention also relates to the use of such compounds and compositions, in particular to their use when administered to patients to provide a therapeutic effect in disorders involving CB receptors, or which can be treated by acting on said receptors. The compounds have the formula (I) in which the symbols have the meanings given in the description of the invention

EA201070019A 2007-06-15 2008-06-12 4,5-DIHYDRO- (1H) -PYRAZOL DERIVATIVES AS MODULATORS OF CANANABINOID ST-RECEPTORS EA201070019A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94419407P 2007-06-15 2007-06-15
EP07110327 2007-06-15
PCT/EP2008/057367 WO2008152086A2 (en) 2007-06-15 2008-06-12 4,5-dihydro-(1h)-pyrazole derivatives as cannabinoid cb1 receptor modulators

Publications (1)

Publication Number Publication Date
EA201070019A1 true EA201070019A1 (en) 2010-06-30

Family

ID=41571026

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201070019A EA201070019A1 (en) 2007-06-15 2008-06-12 4,5-DIHYDRO- (1H) -PYRAZOL DERIVATIVES AS MODULATORS OF CANANABINOID ST-RECEPTORS

Country Status (8)

Country Link
EP (1) EP2158184A2 (en)
JP (1) JP2010530367A (en)
KR (1) KR20100020998A (en)
AU (1) AU2008263915A1 (en)
CA (1) CA2688208A1 (en)
EA (1) EA201070019A1 (en)
IL (1) IL202299A0 (en)
WO (1) WO2008152086A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100995882B1 (en) * 2010-06-08 2010-11-22 에이치 엘 지노믹스(주) Process for preparing intermediate of pitavastatin or its salt

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03009439A (en) * 2001-09-21 2004-02-12 Solvay Pharm Bv 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity.
IL160081A0 (en) * 2001-09-21 2004-06-20 Solvay Pharm Bv Novel 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
WO2005074920A1 (en) * 2004-01-30 2005-08-18 Solvay Pharmaceuticals B.V. 1,3,5-trisubstituted 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity

Also Published As

Publication number Publication date
EP2158184A2 (en) 2010-03-03
CA2688208A1 (en) 2008-12-18
WO2008152086A3 (en) 2009-05-28
JP2010530367A (en) 2010-09-09
IL202299A0 (en) 2010-06-30
AU2008263915A1 (en) 2008-12-18
KR20100020998A (en) 2010-02-23
WO2008152086A2 (en) 2008-12-18

Similar Documents

Publication Publication Date Title
EA200870074A1 (en) DERIVATIVES OF 4,5-DIHYDRO- (1H) -PYRAZOLE AS A MODEL OF CAN1ABINOID RECEPTOR CB1
GEP20135907B (en) L-(piperidin-4-yl)-pyrazole derivatives as gpr 119 modulators
EA200900658A1 (en) DERIVATIVES OF INDASOLYL ETHERS OR AMIDES FOR THE TREATMENT OF DISORDERS MEDIATED BY GLUCOCORTIA RECEPTORS
NO20084489L (en) Azolopyrimidines as inhibitors of cannabinoid 1 activity
BRPI0507005A (en) compounds, pharmaceutical compositions, use of a compound, and method of preparing a pharmaceutical composition
MY143565A (en) Novel fluorocglycoside derivatives of pyrazoles: medicaments containing these compounds, and the use thereof
NO20090064L (en) Pyrasols as glucokinase activators
PL2150530T3 (en) Substituted sulfonamide derivatives
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
UA99524C2 (en) Triazole derivatives useful for the treatment of diseases
WO2009010455A3 (en) Pyrazole derivatives as modulators of metabotropic glutamate receptors
EA201001682A1 (en) Derivatives of phenyl and benzodioxynyl-substituted indazols
MY149855A (en) Benzimidazole derivatives and their use for modulating the gaba? receptor complex
MY183111A (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
CY1109569T1 (en) Substituted cyclohexane-1,4-diamine derivatives
EA200870606A1 (en) SERO-CONTAINING DERIVATIVES OF PYRAZOL AS AN ELECTORAL ANTAGONISTS OF CANA CANNABINOID RECEPTOR
MX2007012624A (en) Benzimidazole derivatives and their use for modulating the gabaa receptor complex.
TW200730500A (en) 4, 5-dihydro-(1H)-pyrazole derivatives as cannabinoid CB1 receptor modulators
EA201070019A1 (en) 4,5-DIHYDRO- (1H) -PYRAZOL DERIVATIVES AS MODULATORS OF CANANABINOID ST-RECEPTORS
WO2009037244A3 (en) 5-aryl-4,5-dihydro-(1h)-pyrazoles as cannabinoid cb1 receptor agonists
EA201070381A1 (en) 5-aryl-4,5-dihydro- (1H) -pyrazoles as agonists of cannabioid heat receptor
EA201490618A1 (en) SUBSTITUTED 2- (CHROMAN-6-ILOXI) THIAZOLES AND THEIR USE AS PHARMACEUTICAL FACILITIES
UA92736C2 (en) 1h-imidazole derivatives as cannabinoid cb2 receptor modulators
WO2013048989A3 (en) Pyrazole compounds
MX2009013677A (en) 4,5-dihydro-(1h)-pyrazole derivatives as cannabinoid cb1 receptor modulators.